Bharat Biotech Covaxin

After Covaxin, Bharat Biotech to now begin trials for intranasal COVID-19 vaccine from Feb-March

BBV154 (intranasal COVID-19 vaccine), preclinical testing has been completed for toxicology, immunogenicity and challenge studies. These studies have been conducted in the USA and India

Coronavirus News Updates: COVID-19 vaccination dry run at six sites in Uttar Pradesh from 5 January

Coronavirus News Updates: In a statement, the state government said the dry run will start at 10 am in three urban and as many rural sites with a minimum of two sessions

Bharat Biotech underplays adverse event in Covaxin Phase 1 trial as start date for Phase 3 nears

The volunteer, who had no comorbidities, developed viral pneumonitis after being given a dose of the COVAXIN shot.

Covaxin, Bharat Biotech's COVID-19 vaccine candidate, gets DCGI nod for Phase 3 trials

The phase 3 trials will be conducted in 19 sites across 10 states, including in cities such as Delhi, Mumbai, Patna and Lucknow and would seek to enroll 28,500 volunteers aged 18 years and above.

Coronavirus vaccine may hit Indian market by first quarter of 2021, says health minister Harsh Vardhan

Two homegrown vaccine candidates — Covaxin by Bharat Biotech and ZyCOV-D by Zydus Cadila — have almost finished the phase II clinical trials

Emerging landscape of COVID-19 vaccines in India, 14 Aug: Bharat Bio, Zydus move to Phase 2; Biological E, Bayor College tie up for COVID-19 vaccine

Over a dozen Indian companies are in partnership with other firms and institutes to bring a preventive vaccine into global markets by 2021.

Coronavirus Updates: BMC sero-survey in three wards shows 57% prevalence of COVID-19 in slums, 16% in other areas

Coronavirus LIVE Updates: The BMC on Tuesday said that a serological surveillance for COVID-19 infection was commissioned by NITI-Aayog, Municipal Corporation of Greater Mumbai and Tata Institute of Fundamental Research.

Scientists caution govt over plans to fast-track 'Made in India' vaccine, COVAXIN

A virologist said that a vaccine normally takes at least 12-18 months to pass all necessary clinical trial phases while the company developing it has just over a month to wrap up everything

COVID-19 vaccine: ICMR urges institutes chosen for Bharat Biotech's COVAXIN to complete recruitment for human trials by 7 July

The ICMR envisages launching the vaccine for public health use by 15 August after completion of all clinical trials, as per a letter to institutions conducting trials.